At a Glance
- Company: Vivacta Biotechnology (Shanghai)
- Location: Shanghai, China
- Funding: $50M+ (Series A/A+)
- Lead investors: Loyal Valley Capital, Decheng Capital
- Focus: GT801 in vivo CAR-T for CD19+ B-cell cancers
What happened?
Vivacta Biotechnology closed an oversubscribed Series A and Series A+ financing totalling over US$50 million on 29 April 2026. Series A led by Loyal Valley Capital; Series A+ by Decheng Capital, with OrbiMed, Hankang Capital, Eisai Innovation, C&D Emerging, Qiming Venture Partners, Beijing Shunxi and Apricot Capital participating.
Why does it matter?
Vivacta pioneers in vivo CAR-T, delivering CAR genes directly to patient T-cells via lipid nanoparticles — avoiding ex vivo manufacturing bottlenecks. GT801 targets CD19+ relapsed/refractory B-cell malignancies; Phase 1 data at ASH 2025 supported dose escalation.
Who’s behind it?
Shanghai-based Vivacta focuses on revolutionising CAR-T accessibility. New board members: Xie Ronggang (Loyal Valley), Decheng partner. Funds fuel global expansion.
How was it achieved?
Proceeds advance GT801 Phase 1/2 trials, regulatory submission, platform expansion and team growth. Builds on first-in-human safety/efficacy data.
What’s next?
GT801 regulatory filing, additional indications, international footprint. Aims to make in vivo CAR-T standard for liquid/solid tumours.
What are people saying?
Vivacta: “Global capital validates innovative technologies… accelerates clinical/global operations.”